Suven Pharma Q4FY22 PAT up 10.29% at Rs91.67 crore yoy on EBITDA margin expanding sharply to 58.6%

9 May 2022 , 02:39 PM

Suven Pharma Ltd reported 40.39% growth in sales revenues yoy for the Q4FY22 quarter on consolidated basis at Rs363.85 crore.

On a sequential basis, revenues were lower for the quarter by -7.08%. For the full year FY22, the revenues were higher by 30.7% at Rs1,320 crore. Suven Pharma is focused entirely on the high growth contract development and manufacturing operations (CDMO).

The company has declared dividend of Rs.1 per share plus a special dividend of Rs.1 per share. It has taken over 100% of Casper Pharma.

The consolidated net profit for Q4FY22 was up 10.29% at Rs91.67 crore while it was down on a sequential basis by -42.73%.

There was a sharp expansion in the EBITDA and the EBITDA margins but there was a sharp spike in the cost of raw materials consumed in the quarter which grew by 49% yoy at Rs1,303 crore. This was partially compensated by inventory efficiency gains.

Net margins stood at 25.19% in Q4FY22 quarter compared to 32.07% in Q4FY21. NPM was lower sequentially against 40.88% in Q3FY22.

Financial highlights for Mar-22 compared yoy and sequentially

	Suven Pharma
Rs in Crore	Mar-22	Mar-21	YOY	Dec-21	QOQ
Total Income (Rs cr)	₹ 363.85	₹ 259.17	40.39%	₹ 391.59	-7.08%
Net Profit (Rs cr)	₹ 91.67	₹ 83.12	10.29%	₹ 160.07	-42.73%
Diluted EPS (Rs)	₹ 3.60	₹ 3.27		₹ 6.29
Net Margins	25.19%	32.07%		40.88%